Kelly Ann Botta, PA-C | |
340 N Pleasant Valley Rd, Winchester, VA 22601-5608 | |
(406) 926-1325 | |
(540) 900-0959 |
Full Name | Kelly Ann Botta |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 340 N Pleasant Valley Rd, Winchester, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215259668 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | 0110003257 (Virginia) | Secondary |
363A00000X | Physician Assistant | 0110003257 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kelly Ann Botta, PA-C 340 N Pleasant Valley Rd Po Box 4164, Winchester, VA 22601 Ph: (540) 692-6132 | Kelly Ann Botta, PA-C 340 N Pleasant Valley Rd, Winchester, VA 22601-5608 Ph: (406) 926-1325 |
News Archive
Four Senators addressed the hundreds of home care and hospice providers today that have come to our nation's capitol to keep the fight alive for the critical, high-value, high-quality care that is offered to millions of vulnerable citizens in this country.
The nucleic acids of DNA encode genetic information, while the amino acids of proteins contain the code to turn that information into structures and functions. Together, they provide the two fundamental codes underlying all of life.
The novel coronavirus emerged in December 2019 in Wuhan City, Hubei Province, in China, and since then, it has rapidly spread to over 170 countries across the globe. Our knowledge of the virus, now officially named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still in the early stages. However, scientists around the world are racing to better understand the virus, in the hope of shedding light on potential vaccines and therapies.
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
› Verified 7 days ago